Post-Marketing Surveillance Study to Monitor Safety of Vaccination (Accor to Prescribing Information) With GlaxoSmithKline Biologicals Human Papillomavirus Vaccine (HPV-16/18 L1/AS04) in Healthy Filipino Females (3,000; Aged greater than or equal to 10 Yrs).

Trial Profile

Post-Marketing Surveillance Study to Monitor Safety of Vaccination (Accor to Prescribing Information) With GlaxoSmithKline Biologicals Human Papillomavirus Vaccine (HPV-16/18 L1/AS04) in Healthy Filipino Females (3,000; Aged greater than or equal to 10 Yrs).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 14 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Dec 2010 Planned end date changed from Nov 2009 to Apr 2012 as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top